irofulven has been researched along with Hematologic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ | 1 |
| Baker, SD; Britten, CD; Clark, GM; Drengler, R; Eckhardt, SG; Felton, S; Hammond, LA; Hidalgo, M; Kuhn, JG; MacDonald, JR; Moczygemba, J; Rowinsky, EK; Siu, L; Smith, C; Smith, SL; Villalona-Calero, MA; Von Hoff, DD; Weitman, S | 1 |
1 trial(s) available for irofulven and Hematologic Diseases
| Article | Year |
|---|---|
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting | 2004 |
1 other study(ies) available for irofulven and Hematologic Diseases
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting | 2000 |